Originally published by our sister publication Clinical Oncology News
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.
Efficacy was evaluated in CheckMate 76K, a randomized, double-blind trial enrolling 790 patients with stage IIB/C melanoma. Patients were randomized (2:1) to nivolumab 480 mg or placebo by IV infusion every four weeks for up to one year or until disease recurrence